Paul Minshull is the Founder and Chief Executive Officer of Scarsin Corporation and a leading authority in global forecasting methodologies and technology enablement. He founded Scarsin in 2002 with a mission to improve the quality and accuracy of financial forecasting, particularly in the life sciences industry. The company’s technology is used by global organizations including Bayer, Eli Lilly, Gilead and Pfizer. In response to the coronavirus pandemic, Paul redeployed an expert team to build a best practice forecasting solution to support public and private sector responses. Based in Markham, ON, the Scarsin team has deployed hundreds of global forecasting solutions, covering more than 100 diseases.
Prior to founding Scarsin, Paul led the CNS team at Eli Lilly, overseeing products including Prozac, Zyprexa, and Cymbalta. Paul is a frequent speaker and panel expert at conferences world-wide. He has an undergraduate degree and MBA, both from McMaster University.
